World-leading Complement System expertise 

Complement Therapeutics is a spin-out from The University of Manchester. Its founders have international reputations and world-leading Complement System expertise. 

In particular, the ground breaking research conducted by the founders has led to valuable new insights regarding the role of complement in both ocular and systemic diseases. Of particular note is the research conducted into the role of FHR proteins in age-related macular degeneration (Cipriani and Clark et al., Nat. Comm., 2020, Cipriani and Unwin et al., Am J Hum Genet, 2021).

Based on such insights, the company is focused on the research and development of novel therapeutic approaches to address unmet needs in diseases related to complement dysregulation. 

In developing such therapies, multiple platforms are being pursued including AAV gene therapies as well as protein-based approaches, building on our original patented research and each with the potential to transform lives. 

Alongside our therapeutic strategy, the Company has developed a highly novel mass spectrometry platform (the Complement Precision Medicine platform) enabling the simultaneous measurement of >30 complement proteins from a systemic blood sample.